Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Combination Therapy Could Be Effective Against Ovarian Cancer

XTALKS VITALS NEWS

Combination Therapy

According to the study authors, the triple drug combination therapy could be an effective treatment option for patients whose cancer has developed resistance to chemotherapy and other conventional treatments.

Share this!

November 3, 2016 | by Sarah Hand, M.Sc.

Researchers at Boston University School of Medicine have identified a combination therapy which may be effective against certain types of ovarian cancer. The research was published in the journal, Anticancer Research.

According to the study authors, the triple drug combination therapy could be an effective treatment option for patients whose cancer has developed resistance to chemotherapy and other conventional treatments. The therapy combines a calpain inhibitor, known as calpeptin, with two different histone deacetylase inhibitors, sodium butyrate and suberanilohydroxamic acid (SAHA).

The researchers tested this combination in two ovarian cancer cell lines, CAOV-3 and SKOV-3. They found that this combination therapy was able to inhibit ovarian cancer cell growth, and induce apoptosis in the tumor cells.

While ovarian cancer accounts for just three percent of all cancers affecting women, it is responsible for the majority of cancer deaths when compared to other female reproductive system cancers. Ovarian cancer is often diagnosed after it has metastasized within the pelvis and abdomen, making it harder to treat and often fatal.



Surgery and chemotherapy are the frontline treatments for ovarian cancer. Platinum-based drugs are also commonly used to treat the disease, as few target specific drugs are approved for ovarian cancer.

Interestingly, calpeptin was also found to have epigenetic effects on the cells used in this study. The calpain inhibitor was able to remove methyl tags from select genes.

“Calpeptin possibly has a dual role,” said senior study author Dr. Sibaji Sarkar, of the Cancer Center, Genome Science Institute, Department of Medicine, Boston University School of Medicine. “It can kill cancer cells and in addition, it may act as an epigenetic drug as well.

“We believe that epigenetic drugs alone are not the best choice for cancer therapy. We need other target specific and other types of inhibitors, but the addition of epigenetic drugs can increase the efficacy of the therapy by blocking the expression of growth promoting genes even after remission after standard therapy.”

Previous research conducted by Sakar and colleagues has found that epigenetics play a key role in the generation of cancer progenitor cells, tumor progression and migration, as well as cancer drug resistance. Other studies have supported this idea by showing that epigenetic drugs make drug resistant cancer cells more susceptible to platinum therapies.


Keywords: Combination Therapy, Ovarian Cancer, Epigenetics


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.